Addex Therapeutics Ltd. announced that it has terminated the Phase 2b/3 study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson's disease (PD-LID) due to the slow recruitment of patients. This has been attributed to the consequences of COVID-19 related patient concerns about participation in clinical studies as well as staffing shortages and turnover within study sites.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0734 CHF | +3.38% | +11.89% | +59.57% |
07:02am | Addex to Present at BioEURquity Europe 2024 | DJ |
04-30 | European Equities Traded in the US as American Depositary Receipts Decline | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+59.57% | 10.04M | |
+22.56% | 46.4B | |
-1.51% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.08% | 26.01B | |
-19.17% | 19.52B | |
+29.16% | 12.43B | |
+0.23% | 12.18B | |
-0.35% | 12.13B |
- Stock Market
- Equities
- ADXN Stock
- News Addex Therapeutics Ltd
- Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson's Disease due to Slow Recruitment Rate